Skip to NavigationSkip to content

European Commission agrees deal with Janssen for 200 million doses of its COVID-19 vaccine

Published on 09/10/20 at 01:05pm
Photo by Raysonho @ Open Grid Scheduler / Grid Engine

The European Commission has approved an agreement with Johnson & Johnson for the supply of 200 million doses of Janssen’s coronavirus vaccine. 

The Advance Purchase Agreement will supply the European Union with these vaccine doses, upon approval and authorisation from regulators. The company is also in talks with other national governments and global organisations to make its vaccine candidate, CP-183528, available throughout the world. 

Johnson & Johnson are also setting aside 500 million doses to ensure lower income countries have sufficient access to vaccines, delivered through international schemes. 

Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Offficer at J&J, said: “The COVID-19 pandemic continues to threaten communities worldwide and we have a responsibility to ensure access to our COVID-19 vaccine as soon as we can. We appreciate the Commission’s and the Member States’ support for our COVID-19 vaccine candidate and development efforts.”

J&J is currently testing a single dose regimen of the vaccine in Phase 3 trials, while a second Phase 3 study with a two-dose regimen is expected to start later this year.

This marks the third vaccine agreement between a pharmaceutical company and the European Commission. Sanofi and AstraZeneca have made agreements to provide 300 million doses each. The Commission has also conducted talks with CureVac, BioNTech-Pfizer and Moderna in the pursuit of further deals.

Conor Kavanagh

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches